^
Association details:
Biomarker:MYC expression
Cancer:Multiple Myeloma
Drug:JQ-1 (BET inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

Excerpt:
...the effect of JQ1 was explored in an aggressive, genetically-engineered model of Myc-dependent MM...two animals with advanced disease have completed 14 days of JQ1 treatment (25 mg/kg daily, adjusted to tolerability). Both animals reveal objective evidence of response by measurement of monotypic serum immunoglobulins, including a complete response (CR) in the second animal...An unexpected finding was the observed, robust inhibition of MYC expression following treatment with JQ1...
DOI:
10.1016/j.cell.2011.08.017